Cytoprotective And Supportive Care Agents

Certain Sandostatin Strengths Discontinued

By May 01, 2017

The decision to discontinue Sandostatin 200mcg and 1000mcg is not due to manufacturing, product quality, safety, or efficacy concerns, according to the Company.

Cytoprotective Agent Ethyol Now Available

By September 26, 2016

Cumberland announced the relaunch of Ethyol (amifostine) for Injection indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, and to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.

FDA Approves Updated ONJ Warning for Prolia, Xgeva

By August 09, 2016

The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen's Prolia (denosumab) and Xgeva (denosumab).

First Emergency Tx Approved for 5-FU, Capecitabine Overdose

By December 11, 2015

The FDA has approved Wellstat Therapeutics' Vistogard (uridine triacetate) oral granules, the first treatment for patients following an overdose of 5-fluorouracil (5-FU) or capecitabine,

Adjunctive Telotristat Demonstrates Efficacy in Carcinoid Syndrome

By August 03, 2015

Lexicon announced top-line results from the Phase 3 study, TELESTAR, which evaluated oral telotristat etiprate in cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care.

Pulmonary HTN Reported With Proglycem in Newborns, Infants

By July 16, 2015

The Food and Drug Administration (FDA) has issued a warning that pulmonary hypertension has been reported in infants and newborns treated with Proglycem (diazoxide; Teva) for low blood glucose.

Cannabis Helpful for Cancer-Linked Symptoms, But Quality Studies Needed

December 18, 2014

Cannabis and cannabinoid pharmaceuticals can be helpful for nausea and vomiting, pain, and weight loss associated with cancer.

Xgeva Gains Hypercalcemia of Malignancy Indication

December 08, 2014

Amgen announced that the Food and Drug Administration (FDA) has approved Xgeva (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

Akynzeo Approved for Chemotherapy-Induced Nausea, Vomiting

October 10, 2014

The Food and Drug Administration (FDA) has approved Akynzeo (netupitant and palonosetron; Eisai) to treat nausea and vomiting in patients undergoing cancer chemotherapy.

Rolapitant NDA Submitted for Chemotherapy-Induced Nausea and Vomiting

September 09, 2014

Tesaro has submitted a New Drug Application (NDA) to the FDA for approval of oral rolapitant for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Emend Shows Potential in Pediatric Chemotherapy-Induced Nausea, Vomiting

June 30, 2014

Merck announced results from a Phase 3 Emend (aprepitant) study in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years.

Medical Practice Pleads Guilty to Unapproved Cancer Drugs

June 26, 2014

A medical practice in KY has pleaded guilty to federal charges regarding the purchasing and selling of unapproved and improperly labeled chemotherapy drugs.

Reducing Cancer Care Cost Sans Patient Risk

March 10, 2014

Experts have identified three major sources of high cancer costs and argue that cancer doctors can likely reduce them without harm to patients. The cost-cutting proposals call for changes in routine clinical practice involved in end-of-life care, medical imaging, and drug pricing.

USPSTF: Evidence Lacking for Vitamin Prevention of CVD, CA

February 25, 2014

The USPSTF has found that insufficient evidence to evaluate the benefits and harms of multivitamins and most single- or paired-nutrient supplements for the prevention of cardiovascular disease and cancer.

Patients Are 'Myth'-Informed About Their Risk of Cancer

February 04, 2014

Fewer than half of Americans are aware that body weight and physical activity affect cancer risk.

First- and Second-Generation Family Hx Adequate in Oncology

February 04, 2014

Recommendations relating to the key elements of minimum adequate cancer family history are detailed, although they are often incompletely implemented.

Exercise Important for Men After Cancer Diagnosis

January 28, 2014

Men who are physically active after a cancer diagnosis have significantly improved survival.

Has the 'War on Cancer' Made Progress?

January 24, 2014

More people are being diagnosed with and dying from cancer, but this is largely the result of declines in mortality from other causes.

Prognostic Tool ID's Risk of Death for Hospital Patients

December 17, 2013

A validation study has confirmed that the CARING criteria may be used upon admission to estimate the risk of death at one year for inpatients in broad hospital settings.